NL-OMON44198已完成不适用
Randomized, double-blind, double-dummy, placebo-controlled, four-way crossover single dose<br>study to determine the test-retest reliability of, and the effect of oral valproic acid, levetiracetam and<br>lorazepam on, cortical excitability measurements in healthy volunteers as measured by TMS-EEG and TMS-EMG. - Cortical excitability study in healthy volunteers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Healthy male subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, and urinalysis.
- •2. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and with a minimum weight of 50 kg.
- •3. Able to participate and willing to give written informed consent and to comply with the study restrictions.
排除标准
- •1. Legal incapacity or inability to understand or comply with the requirements of the study.
- •2. Positive test for drugs of abuse at screening or pre-dose.
- •3. History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption will be prohibited during study confinement and at least 24 hours before screening, before dosing, and before each scheduled visit.
- •4. History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder.
- •5. A history of epilepsy or febrile seizures.
- •6. Having metal objects in brain or skull.
- •7. Having a cochlear implant or implanted deep brain stimulator.
- •8. Abnormal sleeping pattern (e.g. working night shifts)
- •9. Resting motor threshold (rMT) of more than 83% of the maximum stimulator output, measured using TMS-EMG during screening.
- •10. History of active malignancy within the last 5 years, with the exception of localized or in situ carcinoma (e.g., skin basal or squamous cell carcinoma).
- •11. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- •12. Systolic blood pressure (SBP) greater than 140 or less than 90 mmHg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mmHg.
- •13. Use of any medications (prescription or over-the-counter [OTC]), vitamin, mineral, herbal, and dietary supplements within 14 days of study drug administration, or less than 5 half-lives (whichever is longer). Exceptions will only be made if the rationale is discussed and clearly documented by the Investigator.
- •14. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis). In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
- •15. Participation in an investigational drug or device study within 3 months prior to screening.
- •16. Any blood donation or other loss of blood greater than 500 mL within 3 months of screening or plasma donation within 2 weeks of screening.
- •17. Concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead electrocardiogram (ECG)). Minor deviations from the normal range may be accepted, if judged by the Investigator to have no clinical relevance.
- •18. Use of tobacco or nicotine products within the previous month before the first dose administration.
- •19. Clinically significant abnormalities in ECG, as judged by the Investigator, including evidence of atrial fibrillation, atrial flutter, complete branch block, Wolf-Parkinson-White Syndrome, or cardiac pacemaker.
- •20. Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable).
研究者
相似试验
进行中（未招募）
1 期
T-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitisAcute Ulcerative Colitis (UC)MedDRA version: 16.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2012-003702-27-LTDr. Falk Pharma GmbH762
进行中（未招募）
1 期
T-02 (gastro-resistant phosphatidylcholine granules) vs. placebo vs. mesalamine for maintenance of remission in patients with ulcerative colitisMaintenance of remission in ulcerative colitis (UC)MedDRA version: 17.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-001205-84-LVDr. Falk Pharma GmbH400
进行中（未招募）
1 期
T-02 (gastro-resistant phosphatidylcholine granules) vs. placebo vs. mesalamine for maintenance of remission in patients with ulcerative colitisEUCTR2013-001205-84-DEDr. Falk Pharma GmbH400
撤回
3 期
Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastro-resistant phosphatidylcholine (LT-02) versus placebo versus mesalamine for maintenance of remission in patients with ulcerative colitisColitis Ulcerosaremission10017969NL-OMON42465Dr Falk Pharma GmbH28
进行中（未招募）
1 期
T-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitisEUCTR2012-003702-27-DEDr. Falk Pharma GmbH762